Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.
Key Details
- 1Median Technologies received FDA clearance for Eyonis LCS, an AI/ML-powered computer-aided detection software as a medical device.
- 2Designed to assist in the interpretation of low-dose CT (LDCT) scans for lung cancer screening, addressing inter-reader variability.
- 3Eyonis LCS is reported as the first end-to-end FDA-cleared device specifically for lung cancer screening workflows.
- 4Performance testing showed 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value (NPV).
- 5The tool is aimed at improving screening access and diagnostic accuracy, as well as reducing unnecessary procedures.
Why It Matters
FDA clearance for Eyonis LCS marks a significant advancement in AI-assisted lung cancer screening by leveraging CT imaging. The device's strong performance metrics and focus on workflow efficiency could help radiology practices meet increasing screening demands while improving patient outcomes.
Source
Radiology Business
Related News
•AuntMinnie
AI Model Predicts Dosimetry for Lu-177 PSMA Therapy Using PET/CT
A machine learning PET/CT model shows promise for predicting radiation dose prior to Lu-177 PSMA therapy in prostate cancer patients.
•Radiology Business
DeepHealth's Prostate AI Gains FDA Clearance for MRI Workflows
DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.
•AuntMinnie
Human-AI Collaboration Achieves 99.2% Sensitivity for PE Detection in CTPA
A large study confirms that combining radiologists with FDA-cleared AI significantly improves pulmonary embolism detection on CTPA.